Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Procept Biorobotics Corp (NQ: PRCT )

94.94 +0.49 (+0.52%)
Streaming Delayed Price Updated: 12:05 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Procept Biorobotics Corp

< Previous 1 2 Next >
PROCEPT BioRobotics Corporation Announces Pricing of Offering of Common Stock
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics Corporation Announces Proposed Offering of Common Stock
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics® Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue and Adjusted EBITDA Guidance
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics to Report Third Quarter 2024 Financial Results on October 28, 2024
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics Received U.S. FDA Approval to Initiate Pivotal Randomized Clinical Study for Prostate Cancer
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics to Present at Upcoming 2024 Wells Fargo Healthcare Conference on September 4, 2024
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics Announces FDA Clearance of the HYDROS™ Robotic System, the Next-Generation, AI-Powered Platform for Aquablation® Therapy
Designed to improve efficiency, enhance surgeon and staff experience and deliver a more accurate and consistent treatment plan for better clinical outcomes 
From PROCEPT BioRobotics
Via GlobeNewswire
Is PROCEPT BioRobotics the Next Big Thing in Surgical Robotics?
Surgical robotics company PROCEPT BioRobotics Co. (NASDAQ: PRCT) developed the AquaBeam Robotic System for the treatment of benign prostatic hyperplasia 
Via MarketBeat
Why Intuitive Surgical Stock is Dominating the Medical Sector
Robotic surgery conjures up futuristic images of automated machines performing surgery on anesthetized human patients in an assembly line. However 
Via MarketBeat
PROCEPT BioRobotics® Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue and EBITDA Guidance
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics to Report Second Quarter 2024 Financial Results on August 1, 2024
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics Announces New CPT® Category I Code from the American Medical Association for Aquablation therapy
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics to Present at Upcoming 2024 Truist Securities MedTech Conference on June 18, 2024
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics to Present at Upcoming 2024 Leerink Partners Healthcare Crossroads Conference and 44th Annual William Blair Growth Stock Conference
From PROCEPT BioRobotics
Via GlobeNewswire
Real-World, Long-Term Data Demonstrate Sustained Benefits of Aquablation Therapy for Men with Benign Prostatic Hyperplasia
Data from the Icahn School of Medicine at Mount Sinai and Potomac Urology presented at the 2024 AUA Annual Meeting highlight Aquablation therapy’s potential to become the new standard of care in BPH... 
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
From PROCEPT BioRobotics
Via GlobeNewswire
Late Breaking Abstract Presented at the Japanese Urological Association Annual Meeting on Aquablation Therapy Outcomes for Men in Japan with Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia
Japanese post market survey supports safety and efficacy of Aquablation therapy 
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics Announces 12 Scientific Research Presentations on Aquablation Therapy for the Treatment of Benign Prostatic Hyperplasia at the 2024 AUA Annual Meeting
Presentations include first published experience report of same-day discharge in an ambulatory surgical center, real-world data outcomes and 5-year data comparison between two FDA trials 
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics Corp. Announces Investor Event at 2024 AUA Annual Meeting in San Antonio, Texas
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics to Report First Quarter 2024 Financial Results on May 1, 2024 and Attend the 2024 Bank of America Healthcare Conference on May 15, 2024
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics Reports Fourth Quarter and Full Year 2023 Results
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics to Present at the 44th Annual TD Cowen Health Care Conference in Boston
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics® Announces Preliminary Fourth Quarter Revenue of $43.3 million to $43.6 million
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics to Present at the 35ᵗʰ Annual Piper Sandler Healthcare Conference in New York City
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics® Reports Third Quarter 2023 Financial Results and Increases 2023 Revenue Guidance
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics to Report Third Quarter 2023 Financial Results on November 1, 2023
From PROCEPT BioRobotics
Via GlobeNewswire
The National Institute for Health and Care Excellence Endorses Aquablation® Therapy with "Standard Arrangements" Recommendation
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics Announces New Corporate Headquarters in San Jose
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics® Receives U.S. FDA Investigational Device Exemption to Investigate Aquablation® Therapy for Prostate Cancer
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics® Announces First Commercial Aquablation Therapy Procedures in Japan
From PROCEPT BioRobotics
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.